Stock Market & Financial Investment News

News Breaks February 15, 2013 07:21 EDT PCYC Pharmacyclics price target raised to $90 from 79 at Credit Suisse Credit Suisse believes Pharmacyclics shares will be driven by a faster path to market for ibrutinib, rapid adoption, and data flow in 2013/2014. Shares are Outperform rated. News For PCYC From The Last 14 Days Check below for free stories on PCYC the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 14:07 EDT PCYC Pharmacyclics drug designated for orphan status for multiple myeloma treatment Subscribe for More Information May 13, 2013 10:09 EDT PCYC On The Fly: Analyst Upgrade Summary Subscribe for More Information 06:33 EDT PCYC Pharmacyclics upgraded to Outperform from Sector Perform at RBC Capital Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.